Absci Corporation, a data-first generative AI drug creation company, announced the initiation of IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody designed using...
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer...